Hunan Fangsheng Pharmaceutical Co., Ltd. (SHA:603998)
China
· Delayed Price · Currency is CNY 9.71
-0.13 (-1.32%)
Apr 30, 2025, 3:00 PM CST
SHA:603998 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2014 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2014 - 2018 |
| Operating Revenue | 1,702 | 1,569 | 1,751 | 1,535 | 1,252 | 1,072 | Upgrade
|
| Other Revenue | 59.09 | 59.09 | 41.27 | 32.12 | 27.15 | 21.9 | Upgrade
|
| Revenue | 1,762 | 1,629 | 1,792 | 1,567 | 1,279 | 1,094 | Upgrade
|
| Revenue Growth (YoY) | 6.81% | -9.12% | 14.36% | 22.54% | 16.91% | 4.06% | Upgrade
|
| Cost of Revenue | 513.12 | 522.25 | 589.28 | 566.27 | 468.18 | 301.16 | Upgrade
|
| Gross Profit | 1,248 | 1,106 | 1,203 | 1,001 | 810.58 | 792.59 | Upgrade
|
| Selling, General & Admin | 841.86 | 804.8 | 940.45 | 798.94 | 635.9 | 642.31 | Upgrade
|
| Research & Development | 154.1 | 107.93 | 70.4 | 51.4 | 53.62 | 41.23 | Upgrade
|
| Other Operating Expenses | 26.07 | 29.27 | 28.55 | 24.33 | 19.41 | 20.94 | Upgrade
|
| Operating Expenses | 1,035 | 942.99 | 1,049 | 877.34 | 718.63 | 708.83 | Upgrade
|
| Operating Income | 213.97 | 163.31 | 153.98 | 123.37 | 91.95 | 83.76 | Upgrade
|
| Interest Expense | -15.9 | -20.81 | -22.95 | -18.39 | -16.83 | -10.82 | Upgrade
|
| Interest & Investment Income | 45.59 | 10.64 | 171 | 1.77 | 3.59 | 18.43 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | 0.16 | -0.57 | - | 0 | Upgrade
|
| Other Non Operating Income (Expenses) | -6.09 | -2.22 | -15.14 | -2.46 | -2.64 | -4.09 | Upgrade
|
| EBT Excluding Unusual Items | 237.58 | 150.92 | 287.05 | 103.72 | 76.07 | 87.28 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -1.23 | -3.59 | Upgrade
|
| Gain (Loss) on Sale of Investments | -5.48 | -5.46 | -0.06 | -21.17 | -22.33 | -0.04 | Upgrade
|
| Gain (Loss) on Sale of Assets | 12.71 | 11.38 | -1.03 | -0.94 | -0.51 | 0.1 | Upgrade
|
| Asset Writedown | -2.38 | - | - | - | - | -0.7 | Upgrade
|
| Other Unusual Items | 52.38 | 46.5 | 40.63 | 9.18 | 16.97 | 11.42 | Upgrade
|
| Pretax Income | 294.8 | 203.34 | 326.57 | 90.79 | 68.97 | 94.48 | Upgrade
|
| Income Tax Expense | 28.4 | 23.71 | 49.87 | 20.87 | 15.2 | 15.5 | Upgrade
|
| Earnings From Continuing Operations | 266.4 | 179.62 | 276.71 | 69.92 | 53.78 | 78.97 | Upgrade
|
| Minority Interest in Earnings | 6.56 | 7.2 | 9.15 | 0.12 | 10.02 | -0.06 | Upgrade
|
| Net Income | 272.96 | 186.82 | 285.85 | 70.04 | 63.79 | 78.91 | Upgrade
|
| Net Income to Common | 272.96 | 186.82 | 285.85 | 70.04 | 63.79 | 78.91 | Upgrade
|
| Net Income Growth | 62.10% | -34.64% | 308.13% | 9.79% | -19.16% | 8.11% | Upgrade
|
| Shares Outstanding (Basic) | 435 | 434 | 433 | 438 | 425 | 415 | Upgrade
|
| Shares Outstanding (Diluted) | 451 | 445 | 433 | 438 | 425 | 438 | Upgrade
|
| Shares Change (YoY) | 4.55% | 2.70% | -1.06% | 2.93% | -2.99% | 2.10% | Upgrade
|
| EPS (Basic) | 0.63 | 0.43 | 0.66 | 0.16 | 0.15 | 0.19 | Upgrade
|
| EPS (Diluted) | 0.61 | 0.42 | 0.66 | 0.16 | 0.15 | 0.18 | Upgrade
|
| EPS Growth | 55.05% | -36.36% | 312.50% | 6.67% | -16.67% | 5.88% | Upgrade
|
| Free Cash Flow | 104.08 | -131.24 | 130.38 | 0.92 | 68.9 | -36.87 | Upgrade
|
| Free Cash Flow Per Share | 0.23 | -0.29 | 0.30 | 0.00 | 0.16 | -0.08 | Upgrade
|
| Dividend Per Share | 0.250 | 0.290 | 0.350 | 0.150 | 0.120 | 0.060 | Upgrade
|
| Dividend Growth | -28.57% | -17.14% | 133.33% | 25.00% | 100.00% | 100.00% | Upgrade
|
| Gross Margin | 70.87% | 67.93% | 67.12% | 63.86% | 63.39% | 72.47% | Upgrade
|
| Operating Margin | 12.15% | 10.03% | 8.59% | 7.87% | 7.19% | 7.66% | Upgrade
|
| Profit Margin | 15.50% | 11.47% | 15.95% | 4.47% | 4.99% | 7.22% | Upgrade
|
| Free Cash Flow Margin | 5.91% | -8.06% | 7.28% | 0.06% | 5.39% | -3.37% | Upgrade
|
| EBITDA | 286.08 | 234.37 | 223.65 | 190.74 | 162.4 | 137.54 | Upgrade
|
| EBITDA Margin | 16.24% | 14.39% | 12.48% | 12.17% | 12.70% | 12.57% | Upgrade
|
| D&A For EBITDA | 72.11 | 71.06 | 69.67 | 67.38 | 70.45 | 53.78 | Upgrade
|
| EBIT | 213.97 | 163.31 | 153.98 | 123.37 | 91.95 | 83.76 | Upgrade
|
| EBIT Margin | 12.15% | 10.03% | 8.59% | 7.87% | 7.19% | 7.66% | Upgrade
|
| Effective Tax Rate | 9.63% | 11.66% | 15.27% | 22.99% | 22.03% | 16.41% | Upgrade
|
| Revenue as Reported | 1,323 | 1,629 | 1,792 | 1,567 | 1,279 | 1,094 | Upgrade
|
| Advertising Expenses | - | 77.28 | 34.32 | - | - | 1.38 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.